All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...

Johnson & Johnson is like the Fort Knox of dividend stocks. The healthcare company has an AAA bond rating. That's tied for ...

Expects more pronounced impact from newly launched products as the year progresses. STELARA biosimilar competition to ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales ...

Johnson & Johnson JNJ-N, fresh off a $14.6-billion deal to buy neurological drugmaker Intra ... noting that sales from Shockwave Medical also helped drive growth. Last year, J&J bought heart ...

The New Jersey-based drugmaker expects 2025 sales of between $90.9 billion and $91.7 billion, and to earn between $10.75 and ...

Johnson & Johnson (NYSE ... Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks » The iconic healthcare company backs its high-yielding ...

Johnson & Johnson (NYSE ... the biggest being its $13.1 billion all-cash deal for Shockwave Medical. It has deployed, announced, or committed $32 billion into inorganic growth opportunities ...